Evidence map›Paper›PMID 27123277›Full record

ArticleMolecular and clinical oncology2016

Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.

Minehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka, Kazuki Shimokawa, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Tomomi Ichikawa, Toru Yamada and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Minehiko InomataFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Ryuji HayashiFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Hiroaki TanakaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Kazuki ShimokawaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Kotaro TokuiFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Chihiro TakaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Seisuke OkazawaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Kenta KambaraFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Tomomi IchikawaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Toru YamadaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Toshiro MiwaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.
Tatsuhiko KashiiDepartment of Medical Oncology, Toyama University Hospital, Toyama 930-0194, Japan.
Shoko MatsuiHealth Administration Center, University of Toyama, Toyama 930-0194, Japan.
Kazuyuki TobeFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to prolong survival in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR-TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression-free survival (6.2 vs. 13.2 months; P<0.01) and overall survival (10.5 vs. 36.1 months; P<0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression-free survival (P=0.05) and overall survival (P<0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. Close observation is required in EGFR mutation-positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR-TKIs.

Indexed as

epidermal growth factor receptorlactate dehydrogenaselung cancerprognosistyrosine kinase inhibitor

Identifiers

PMID27123277
PMCPMC4840529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.